Biopharma Layoff Tracker 2024: Merck, Rapt, Aslan and More Cut Staff

1. Merck Layoffs: Merck has laid off approximately 75-80 employees across multiple groups, affecting its early research division.
2. Rapt Therapeutics Layoffs: Rapt Therapeutics is reducing its workforce by 47 people, or about 40% of its existing headcount, to conserve cash resources.
3. Aslan Pharmaceuticals Liquidation: Aslan Pharmaceuticals has terminated all its employees and is liquidating its assets due to financial difficulties.
4. Novartis Layoffs: Novartis has let go of 29 employees in San Diego and plans to eliminate around 100 more jobs as it winds down its development site there.
5. Caribou Biosciences Layoffs: Caribou Biosciences has laid off 21 people, or 12% of its workforce, as it discontinues preclinical development of allogeneic CAR-NK therapies.
6. Roche's Spark Therapeutics Layoffs: Spark Therapeutics is laying off staffers and halting some early-stage programs.
7. Indivior Layoffs: Indivior will cease sales and marketing of its schizophrenia drug Perseris and lay off approximately 130 sales staff due to a highly competitive market.
8. Aerovate Therapeutics Layoffs: Aerovate Therapeutics will lay off nearly all of its staff.
9. BioMarin Pharmaceutical Layoffs: BioMarin Pharmaceutical is laying off approximately 170 employees globally, with most affected employees informed on May 14 and the layoffs expected to be completed by the end of July.
10. Pfizer Cost-Cutting Initiative: Pfizer has launched a sweeping cost-cutting initiative aimed at generating $3.5 billion in savings.
11. ADC Therapeutics Layoffs: ADC Therapeutics plans to cut about 17% of its staff, or 54 employees, along with two preclinical programs, following disappointing sales for Zynlonta.
12. Takeda Layoffs: Takeda plans to lay off about 186 employees in Massachusetts, affecting employees in four locations across three cities.
13. Bristol Myers Squibb Layoffs: Bristol Myers Squibb plans to lay off 48 staff members from its Princeton, New Jersey, facility.
14. EQRx Layoffs: EQRx announced plans to cut 170 jobs and several drug candidates as part of a restructuring effort.
15. Mammoth Biosciences Layoffs: Mammoth Biosciences cut 35 jobs in March, shifting its focus from CRISPR diagnostics to therapeutic research.
16. Selecta Biosciences Layoffs: Selecta Biosciences announced plans to cut about 25% of its workforce as part of a capital prioritization initiative.
17. Zymergen Layoffs: Zymergen plans to lay off 27 members of staff in Alameda County, CA, effective June 20.
18. Foundation Medicine Layoffs: Foundation Medicine, Inc., a Roche subsidiary, plans to cut about 135 members of staff as part of a decision to adopt a leaner organizational structure.
19. Enzyvant Therapeutics Layoffs: Enzyvant Therapeutics plans to lay off 20 employees in North Carolina, including some executive positions.
20. Emerald Cloud Lab Layoffs: Emerald Cloud Lab plans to lay off 30 employees from its headquarters in South San Francisco, effective April 30.
21. Nektar Therapeutics Layoffs: Nektar Therapeutics plans to implement a restructuring initiative that includes cutting its workforce in San Francisco by about 60%.
22. Talaris Therapeutics Layoffs: Talaris Therapeutics plans to lay off about 80 employees, including much of its C-suite, following a previous decision to cut about one-third of its staff and axe two clinical trials.
23. Aeglea Biotherapeutics Layoffs: Aeglea Biotherapeutics announced plans to lay off all but about 10 members of its staff as part of a restructuring initiative.
24. Oncocyte Corporation Layoffs: Oncocyte Corporation announced plans to cut its workforce by about 20% in an effort to extend its cash flow into 2024.
25. GentiBio Layoffs: GentiBio, Inc. has laid off an undisclosed number of employees, citing a challenging biotech macroenvironment.